News for European Biotech Acquisition Corp. (EBACU)

Oculis Holding's candidate, OCS-01, is targeting Diabetic Macular Edema, a condition affecting over 37 million patients worldwide. Read more here.

Oculis Announces Public Listing on NASDAQ

Oculis Announces US Public Listing on NASDAQ Closing of business combination with European Biotech Acquisition Corp. creates Nasdaq-listed ophthalmology...

Dutch SPAC European Biotech Acquisition Corp. (EBAC) shareholders have approved a merger with Swiss biotech Oculis, a deal that valued the combined company at around $220M. Read more here.

According to a news release, Oculis officials hope to forward product candidates to address areas of significant medical needs, including diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma, affecting growing patient populations.

Dutch SPAC European Biotech Acquisition Corp. (EBAC) plans to merge with Swiss eye drug developer Oculis in a deal that estimates the enterprise value of the combined company at $220M.

Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology ... | October 17, 2022

Read European Biotech Acquisition Corp. (NASDAQ:EBAC) Short Interest Up 2,112.5% in September at ETF Daily News

Read European Biotech Acquisition (NASDAQ:EBACU) Trading 0.2% Higher at ETF Daily News

Read European Biotech Acquisition (NASDAQ:EBACU) Stock Price Up 0.2% at ETF Daily News